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OBJECTIVE—It has been suggested that retinol-binding protein
4 (RBP4) links adiposity, insulin resistance, and type 2 diabetes.
However, circulating RBP4 levels are also affected by kidney
function. Therefore, the aim of this study was to test whether
RBP4 serum levels are primarily associated with kidney function
or type 2 diabetes.
RESEARCH DESIGN AND METHODS—RBP4 serum concen-
tration was determined by enzyme-linked immunosorbent assay
in 126 nondiabetic and 104 type 2 diabetic subjects. The study
population was divided according to estimated glomerular filtra-
tion rate (eGFR) into the following groups: eGFR90 ml/min per
1.73 m2 (n  53), 60–90 ml/min per 1.73 m2 (n  90), 30–60
ml/min per 1.73 m2 (n  38), and 30 ml/min per 1.73 m2 (n 
49). Each group was subdivided into nondiabetic and type 2
diabetic subjects.
RESULTS—RBP4 serum concentration was elevated (2.65 vs.
2.01 mol/l; P  0.001) and eGFR was reduced (56 vs. 74 ml/min
per 1.73 m2; P 0.001) in type 2 diabetic vs. nondiabetic subjects,
respectively. By stratifying for eGFR, no more differences in
RBP4 serum concentration were detectable between type 2
diabetic and nondiabetic subjects. A linear regression analysis
revealed an influence of eGFR (r  0.477; P  0.001) but not
A1C (r  0.093; P  0.185) on RBP4 serum concentration.
CONCLUSIONS—Existing human data showing elevated RBP4
levels in type 2 diabetic patients may be the result of moderate
renal insufficiency rather than support for the suggestion that
RBP4 links obesity to type 2 diabetes. Diabetes 57:3323–3326,
2008
Retinol-binding protein 4 (RBP4) is a small vis-ceral protein (21 kDa), mainly synthesized inthe liver and catabolized in the kidneys afterglomerular filtration (1). To prevent the renal
loss of RBP4 before delivering its ligand retinol to the
target tissues, RBP4 is complexed by transthyretin, a
homotetrameric protein with a molecular weight of 55
kDa, formerly known as prealbumin (2). RBP4 was re-
cently discussed as a new adipokine that is possibly linked
to insulin resistance and type 2 diabetes (3–5). Although it
is known that RBP4 serum levels are elevated in states of
impaired kidney function (1,6–8) (which is a common
feature of diabetes, metabolic syndrome, and obesity
[9,10]), parameters of kidney function have not been
reported in most of the studies concerning RBP4 and
insulin resistance and/or diabetes (3–5). Therefore, the
aim of this study was to determine whether RBP4 serum
concentration is associated with kidney function rather
than type 2 diabetes.
RESEARCH DESIGN AND METHODS
Serum samples of 230 age-matched subjects (131 male, including 59 with type
2 diabetes, and 99 female, including 45 with type 2 diabetes) were collected by
the Department of Endocrinology, Diabetes and Nutrition and the Department
of Nephrology—both of Charite´-Universita¨tsmedizin Berlin, Campus Ben-
jamin Franklin, Berlin, Germany—and by the Department of Clinical Nutrition
of the German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany.
The study protocol was approved by the ethics committees of the hospitals
and the University of Potsdam. Written informed consent was obtained from
each subject. Blood was taken from antecubital veins after an overnight fast
and centrifuged, and serum was immediately frozen at80°C until processing.
The renal function of all subjects was quantified by the estimated glomerular
filtration rate (eGFR), which was calculated using the simplified Modification
of Diet in Renal Disease (MDRD) formula including serum creatinine concen-
tration, age, and sex (11). The study population was subdivided into nondia-
betic and diabetic subjects, and each subpopulation was assigned according
to eGFR to the following groups: eGFR 90, 60–90, 30–60, and 30 ml/min
per 1.73 m2.
Measurement of laboratory parameters. Anthropometry was performed
by the attending physician as previously described (12). Serum samples were
analyzed for glucose, total cholesterol, LDL and HDL cholesterol, triglycer-
ides, and creatinine with a Cobas Mira Analyzer (Roche, Mannheim, Ger-
many). The intra-assay coefficients of variation (CVs) were as follows:
glucose, 5.5%; total cholesterol, 5.1%; HDL cholesterol, 5.4%; and triglycerides,
5.1%. The amount of A1C was determined by an enzyme-linked immunosor-
bant assay as described elsewhere, with an intra-assay CV of 2.5% (12).
Determination of RBP4 and transthyretin serum concentration. The
RBP4 and transthyretin serum levels were determined by a noncommercial
enzyme-linked immunosorbant assay as previously described (8,13). For
calibration of both assays, RBP4 and transthyretin standards obtained from
human blood were used, respectively (N Protein Standard SL; Dade Behring,
Marburg, Germany), representing the physiological (nontruncated) RBP4 and
transthyretin forms.
Statistical analysis. Statistical analysis was accomplished using SPSS
(version 15.0; SPSS, Chicago). Results are expressed as medians and ranges.
The data were compared using the nonparametric procedures Mann-Whitney
U test and Kruskal-Wallis test as appropriate. Values of P  0.05 were
considered significant.
RESULTS
Anthropometric and clinical data were recorded by the
attending physicians and are presented in Table 1. The
whole type 2 diabetes cohort (n 104) had elevated RBP4
serum levels in comparison with those of the whole
nondiabetes cohort (n  126) (median 2.65 mol/l [range
0.68–8.03] vs. 2.01 mol/l [0.59–7.97]; P  0.001) (Fig. 1),
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confirming former results that RBP4 serum levels are
related to type 2 diabetes (3–5). However, the diabetic
subjects also revealed a reduction in kidney function, as
indicated by a lower eGFR (56.0 ml/min per 1.73 m2
[4–117] for type 2 diabetic subjects vs. 74.1 ml/min per 1.73
m2 [3–126] for nondiabetic subjects; P  0.001) (Fig. 1).
Since the kidneys have a substantial influence on RBP4
metabolism (1,8), we tested whether the difference in
RBP4 serum concentration between diabetic and non-
diabetic subjects is consistent after stratifying for kidney
function. To do so, we evaluated the RBP4 serum concen-
tration of type 2 diabetic and nondiabetic subjects for all
four groups individually; we were unable to detect any
differences between the groups (P  0.410 for all groups)
(Fig. 2). Moreover, although there are no differences in
RBP4 serum levels between type 2 diabetic and non-
diabetic subjects with comparable eGFR, a gradual eleva-
tion of the RBP4 serum concentration was evident with
progression of kidney injury (Fig. 2), resulting in the
highest RBP4 levels for both type 2 diabetic and nondia-
betic subjects measured in the group with eGFR 30
ml/min per 1.73 m2 in comparison with those of type 2
diabetic and nondiabetic subjects in all other groups (P 
0.01 for all groups). For the type 2 diabetic subjects, the
difference in RBP4 serum concentration was also signifi-
cant for the group with eGFR 30–60 ml/min per 1.73 m2 in
comparison with those of the groups with eGFR 90 and
60–90 ml/min per 1.73 m2 (P  0.01 for both). Further-
more, a significant inverse correlation between RBP4
serum concentration and eGFR was found (SpearmanTA
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FIG. 1. RBP4 serum concentration (A) and eGFR (B) in type 2 diabetic
(n  104) and nondiabetic (n  126) subjects.
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correlation coefficient rs  0.452; P  0.001). Finally,
linear regression analysis with RBP4 as the dependent
variable and including BMI, systolic and diastolic blood
pressure, eGFR, and A1C (Table 2) revealed that eGFR
(standardized -coefficient  0.482; P  0.001) but not
A1C (standardized -coefficient  0.093; P  0.185) influ-
cences RBP4 serum levels. This model was recalculated
using either the presence of type 2 diabetes or fasting
blood glucose instead of A1C; comparable with A1C, both
parameters (presence of type 2 diabetes and fasting blood
glucose) were not associated with RBP4 serum levels (P
0.551 and P  0.687, respectively).
DISCUSSION
Several studies demonstrated elevated RBP4 serum levels
in subjects with obesity, insulin resistance, or type 2
diabetes (3–5,14,15). Although it is known that kidney
dysfunction results in elevated RBP4 serum concentra-
tions (1,6–8,16) and that not only diabetes but also the
metabolic syndrome and obesity are related to kidney
dysfunction (9,10,17–19), information about the kidney
function (such as serum creatinine concentration, glomer-
ular filtration rate, and proteinuria) are lacking in most of
the studies concerning RBP4 in the complex pathogenesis
of insulin resistance and type 2 diabetes. Therefore, the
aim of this study was to assess the influence of kidney
function on the RBP4 serum concentration in type 2
diabetic and nondiabetic subjects.
By comparing the RBP4 serum concentration of type 2
diabetic and nondiabetic subjects irrespective of kidney
function, we were able to confirm former findings and
detected elevated RBP4 serum levels in type 2 diabetic
subjects (3,4). However, type 2 diabetic subjects also
revealed a diminished eGFR, indicating a reduced kidney
function. Therefore, we stratified all subjects according to
eGFR to evaluate the influence of kidney function on RBP4
serum levels. After stratification, no further differences in
the RBP4 serum concentration were detectable between
diabetic and nondiabetic subjects for each eGFR group.
However, a decline in eGFR was accompanied by a
gradual elevation of RBP4 serum levels in both type 2
diabetic and nondiabetic subjects, which was confirmed
by the results of linear regression analysis, indicating an
influence of eGFR but not of the presence of type 2
diabetes or other parameters of diabetes (A1C, fasting
serum glucose, and BMI) on RBP4 serum concentration.
These data indicate that elevation of RBP4 serum con-
centration is more likely to be caused by the presence of
impaired kidney function rather than type 2 diabetes.
Thus, previously described associations of type 2 diabetes,
the metabolic syndrome, or obesity with elevated serum
RBP4 levels might be explained by the concurrence of
impaired kidney function (1,6–8), which is more com-
monly found in these subjects (9,10). Consequently, we
suggest that future studies investigating the potential role
of RBP4 in the pathogenesis of insulin resistance and/or
type 2 diabetes consider kidney function as a potential
confounder when interpreting the results. However, it
remains to be elucidated whether the increased levels of
RBP4 in states of impaired kidney function contribute to
the manifestation of insulin resistance and type 2 diabetes.
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